It is almost certainly Sarizotan because Anavex only started dosing on June 6, just as Australia's winter was starting. Therefore, the summer they're referring in the article to took place during our winter, well before the first patient was dosed with A273. Given what this article said about the great results, A273 has to do extremely well. The competition that apparently nobody on this MB even knew about should now be a concern to Anavex shareholders.